AEON Biopharma Files 8-K on Director Changes & Compensation

Ticker: AEON · Form: 8-K · Filed: Mar 27, 2025 · CIK: 1837607

Sentiment: neutral

Topics: corporate-governance, officer-changes, director-changes

TL;DR

AEON Biopharma 8-K: Director changes, exec comp, and financials filed March 27.

AI Summary

AEON Biopharma, Inc. filed an 8-K on March 27, 2025, reporting on the departure of directors or certain officers, the election of directors, and compensatory arrangements. The filing also includes Regulation FD disclosures and financial statements/exhibits. The company was formerly known as Priveterra Acquisition Corp. and changed its name on December 22, 2020.

Why It Matters

This filing provides insight into potential leadership changes and executive compensation structures at AEON Biopharma, which can impact investor confidence and strategic direction.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure regarding board and officer changes, not indicating immediate financial distress or significant operational shifts.

Key Players & Entities

FAQ

What specific items are being reported in this 8-K filing by AEON Biopharma?

This 8-K reports on the departure of directors or certain officers, the election of directors, and compensatory arrangements of certain officers, along with Regulation FD disclosures and financial statements and exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on March 24, 2025.

What is AEON Biopharma's principal executive office address?

AEON Biopharma's principal executive office is located at 5 Park Plaza, Suite 1750, Irvine, CA 92614.

What was AEON Biopharma's former company name?

AEON Biopharma, Inc. was formerly known as Priveterra Acquisition Corp.

On what date did AEON Biopharma change its name?

The company changed its name on December 22, 2020.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 27, 2025 regarding AEON Biopharma, Inc. (AEON).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing